注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Arcus Biosciences Inc是一家临床阶段的生物制药公司,专注于开发癌症疗法。该公司的六款在研产品正处于临床开发阶段,其分子是一种抗TIGIT抗体,正在进行两项III期注册研究。该公司的差异化联合疗法正在开发用于治疗多种大型肿瘤类型,包括肺癌、结直肠癌、前列腺癌和胰腺癌。该公司的临床开发管线包括Domvanalimab、AB308、Etrumadenant、Quemliclustat、Zimberelimab和AB521。Domvanalimab是其Fc沉默的抗TIGIT单克隆抗体。AB308是其具有Fc功能的抗TIGIT单克隆抗体。Etrumadenant旨在抑制由A2a和A2b受体介导的肿瘤浸润淋巴细胞和骨髓细胞(树突状细胞、巨噬细胞)的腺苷驱动损伤。Quemliclustat是一种非常有效和选择性的小分子CD73抑制剂。Zimberelimab是其抗PD-1抗体。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Michael Quigley | - | 2021 | Director |
Antoni Ribas | 57 | 2019 | Independent Director & Member of Scientific Advisory Board |
Jeffrey A. Bluestone | 71 | - | Chairman of Scientific Advisory Board |
Kathryn E. Falberg | 63 | 2017 | Independent Director |
David L. Lacey | 72 | 2020 | Independent Director & Member of Scientific Advisory Board |
C. Patrick Machado | 60 | 2019 | Independent Director |
Yasunori Kaneko | 71 | 2015 | Lead Independent Director |
Merdad V. Parsey | 60 | 2020 | Director |
Stefani Spranger | - | 2020 | Member of Scientific Advisory Board |
Andrew J. Perlman | 76 | 2020 | Independent Director |
Nicole Lambert | 50 | 2021 | Independent Director |
Johanna Mercier | 53 | 2024 | Director |
Linda Slanec Higgins | 62 | 2021 | Member of Scientific Advisory Board & Director |
K. Christopher Garcia | - | - | Co-Founder & Member of Scientific Advisory Board |
Terry J. Rosen | 64 | 2015 | Co-Founder, Chairman & CEO |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核